Lin-run Wang1, Jian Liu, Ming-zhu Huang, Nong Xu. 1. Department of Clinical Pharmacy, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China. linrunw@yahoo.com.cn
Abstract
OBJECTIVE: To conduct a randomized comparative trial of pharmacokinetics, efficacy and toxicity profile treatment with 1200 mg/m(2) gemcitabine using standard 30-min infusion or fixed dose rate (FDR) infusion [10 mg/(m(2) x min)] on days 1 and 8 plus carboplatin AUC (area under curve) 5 on day 1 in Chinese non-small-cell cancer patients. Twelve patients were enrolled in this study. METHODS:Plasma gemcitabine concentrations were measured by ion-pair reversed phase high performance liquid chromatography. Antitumoral activity and toxicity of gemcitabine was assessed according to World Health Organization criteria. RESULTS: The obtained mean parameters, such as T(1/2) (elimination half time), AUC, and CL (clearance), were consistent with those reported in literature. Qualified response rate in our study was 33.3% for standard arm and 50% for FDR arm. Additional 50% and 33.3% patients contracted stable disease (SD) in standard arm and FDR arm, respectively. The predominant toxicity was hematologic, and patients in the standard infusion arm experienced consistently more hematologic toxicity. CONCLUSION: Pharmacokinetic and clinical data in this trial support the continued evaluation of the FDR infusion strategy with gemcitabine.
RCT Entities:
OBJECTIVE: To conduct a randomized comparative trial of pharmacokinetics, efficacy and toxicity profile treatment with 1200 mg/m(2) gemcitabine using standard 30-min infusion or fixed dose rate (FDR) infusion [10 mg/(m(2) x min)] on days 1 and 8 plus carboplatin AUC (area under curve) 5 on day 1 in Chinese non-small-cell cancerpatients. Twelve patients were enrolled in this study. METHODS: Plasma gemcitabine concentrations were measured by ion-pair reversed phase high performance liquid chromatography. Antitumoral activity and toxicity of gemcitabine was assessed according to World Health Organization criteria. RESULTS: The obtained mean parameters, such as T(1/2) (elimination half time), AUC, and CL (clearance), were consistent with those reported in literature. Qualified response rate in our study was 33.3% for standard arm and 50% for FDR arm. Additional 50% and 33.3% patients contracted stable disease (SD) in standard arm and FDR arm, respectively. The predominant toxicity was hematologic, and patients in the standard infusion arm experienced consistently more hematologic toxicity. CONCLUSION: Pharmacokinetic and clinical data in this trial support the continued evaluation of the FDR infusion strategy with gemcitabine.
Authors: P Bhargava; J L Marshall; K Fried; M Williams; P Lefebvre; W Dahut; J Hanfelt; E Gehan; M Figuera; M J Hawkins; N A Rizvi Journal: Cancer Chemother Pharmacol Date: 2001-08 Impact factor: 3.333
Authors: J R Kroep; G Giaccone; D A Voorn; E F Smit; J H Beijnen; H Rosing; C J van Moorsel; C J van Groeningen; P E Postmus; H M Pinedo; G J Peters Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: Stacy S Shord; Stephanie R Faucette; Heidi H Gillenwater; Scott L Pescatore; Roy L Hawke; Mark A Socinski; Celeste Lindley Journal: Cancer Chemother Pharmacol Date: 2003-03-13 Impact factor: 3.333
Authors: Margaret Tempero; William Plunkett; Veronique Ruiz Van Haperen; John Hainsworth; Howard Hochster; Renato Lenzi; James Abbruzzese Journal: J Clin Oncol Date: 2003-07-28 Impact factor: 44.544
Authors: J L Abbruzzese; R Grunewald; E A Weeks; D Gravel; T Adams; B Nowak; S Mineishi; P Tarassoff; W Satterlee; M N Raber Journal: J Clin Oncol Date: 1991-03 Impact factor: 44.544
Authors: Elaine A Leite; Cristina M Souza; Alvaro D Carvalho-Júnior; Luiz G V Coelho; Angela M Q Lana; Geovanni D Cassali; Mônica C Oliveira Journal: Int J Nanomedicine Date: 2012-10-09